SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-367488
Filing Date
2017-12-12
Accepted
2017-12-12 16:27:57
Documents
5
Period of Report
2017-12-12
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d481969d8k.htm 8-K 17058
2 EX-3.1 d481969dex31.htm EX-3.1 25626
3 EX-3.2 d481969dex32.htm EX-3.2 156616
4 EX-99.1 d481969dex991.htm EX-99.1 4780
5 GRAPHIC g481969g10m82.jpg GRAPHIC 2031
  Complete submission text file 0001193125-17-367488.txt   208281
Mailing Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 171252097
SIC: 2836 Biological Products, (No Diagnostic Substances)